Peptide

Triptorelin (Trelstar)

FDA-approved product existsGH axis & hormones
Not yet scored

BioHarmony verdict

Awaiting review

No BioHarmony report yet. It is queued for review; until then, rely on the status and sources below.

What is Triptorelin (Trelstar)?

FDA-approved triptorelin is marketed as Trelstar depot formulations for palliative treatment of advanced prostate cancer, with product-specific dosing intervals.

Dosing as published

Approved labelTRELSTAR prescribing information for advanced prostate cancer
PopulationAdults covered by the approved TRELSTAR indication
Dose3.75 mg every 4 weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks; strengths are not additive or interchangeable by simple summation.
RouteSingle intramuscular injection in either buttock
FrequencyEvery 4, 12, or 24 weeks according to the selected formulation
DurationLong-term use within the approved indication
PreparationLyophilized microsphere suspension supplied with its formulation-specific diluent and MIXJECT transfer system; reconstitute only as directed for the selected 3.75 mg, 11.25 mg, or 22.5 mg product and administer immediately.
Source: Dosage and Administration sections 2.1-2.2; Instructions for Reconstitution

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved
Last checked2026-07-13
Next review2026-10-11

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.